- The disease
- Metastatic castration-resistant prostate cancer (mCRPC) is prostate cancer that has spread beyond the prostate and continues to grow despite surgical or medical suppression of testosterone. It is an advanced stage of disease for which multiple systemic therapies exist but outcomes remain poor for many patients. The condition is defined by both the spread of cancer to distant sites and the failure of hormone-deprivation therapy to control tumour growth.
- What the asset is trying to do
- TLX591 (177Lu-TLX591) is a radioligand therapy that combines a targeting molecule directed at PSMA (prostate-specific membrane antigen, a protein highly expressed on prostate cancer cells) with lutetium-177, a radioactive isotope that emits beta radiation. The radioligand is designed to bind to PSMA-expressing cancer cells and deliver localised radiation directly to tumour tissue. This approach differs from conventional systemic chemotherapy or androgen-receptor-pathway inhibitors in that it uses a cell-surface protein as a homing target for cytotoxic radiation, rather than blocking tumour-growth signalling pathways.
- What the trial is measuring, and why it matters
- The ProstACT Global trial (NCT06520345) studies 177Lu-TLX591 added to standard of care (SOC) versus SOC alone in patients with mCRPC (per ClinicalTrials.gov NCT06520345). SOC comparator arms include enzalutamide, abiraterone, and docetaxel (per ClinicalTrials.gov NCT06520345). primary endpoint details from the trial protocol, as the specific primary endpoint measure is not disclosed in the available registry data.
- Efficacy benchmarks in this setting
- In the VISION trial, 177Lu-PSMA-617 (lutetium vipivotide tetraxetan, marketed as Pluvicto) plus standard of care demonstrated a median overall survival of 15.3 months versus 11.3 months for standard of care alone in PSMA-positive mCRPC patients who had received prior androgen-receptor-pathway inhibition and taxane-based chemotherapy (per Sartor et al, New England Journal of Medicine 2021). In the TheraP trial, 177Lu-PSMA-617 achieved a prostate-specific antigen (PSA) response rate of 66% compared with 37% for cabazitaxel in men with mCRPC (per Hofman et al, Lancet 2021). These figures are from separate trials with different patient populations, eligibility criteria, and comparator regimens, and are not statistically comparable to early-stage or interim data from TLX591 trials.
- Commercial context